This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content
BROSSARD, Quebec, Sept. 14, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health pathologies using Artificial Intelligence (AI) techniques, announces that the 2026 annual general meeting of shareholders (the “Meeting”) will be held on September 30, 2026, at 10:00 a.m., in person, at Alt Quartier DIX30 Hotel, 6500 de Rome Blvd, 2nd floor, Brossard, QC, J4Y 0B6, for the following purposes:
Sign In or Create an Account
or View more offersArticle content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
- To elect the directors of the Corporation;
- To reappoint Raymond Chabot Grant Thornton, LLP, as independent auditor of the Corporation for the ensuing year and to authorize the directors to establish its remuneration; and
- To transact such other business as may properly come before the Meeting.
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article contentArticle content
Attendance and vote
Article content
All holders of common shares as of August 26, 2026 are entitled to attend and vote at the Meeting in person or by proxy. Instructions on how to vote can be found in the 2026 Management Information Circular which was mailed on September 3, 2026 and is available on www.sedarplus.com.
Article content
The Corporation encourages shareholders to vote early by following the instructions in the meeting materials mailed on September 3, 2026 along with the 2026 Management Information Circular. If you haven’t received your copy, please contact your stockbroker or Computershare Trust Company of Canada at 1-800-564-6253.
Article content
Extension of stock warrants exercise period
Article content
The Corporation would like to inform the stock warrants holders of the following series of the updated expiry dates.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article contentIssuance dateNumber of stock warrantsExpiry date (original)Expiry date (extended)October 25, 20244,603,668April 25, 2026September 25, 2026February 5, 20256,715,369August 5, 2026June 5, 2027 Article content
The exercise price remains unchanged at $0.40. For more information you can contact DIAGNOS at [email protected].
Article content
About DIAGNOS
DIAGNOS is a public Canadian corporation dedicated to the early detection of critical eye-related health problems. By developing innovative products based on AI technologies, DIAGNOS’ solutions provide healthcare clinicians with valuable information that refines diagnostic accuracy, streamlines workflows, and improves patient outcome.
Article content
Additional information is available at www.diagnos.com and www.sedarplus.com.
Article content
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Article content
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Article contentArticle content
Article contentArticle contentArticle contentArticle contentFor further information, please contact: Mr. Marc-André Massue CFO and Secretary DIAGNOS Inc. Tel: 450-678-8882 ext. 235Article content